Our goal is to understand the molecular mechanisms that govern vasculogenesis and angiogenesis. Of primary importance in these processes are the endothelial cells that line the lumen of all blood vessels, playing a key role in the formation, remodeling, and normal physiological function of the vascular system. In addition, endothelial cells are involved in dysfunctional or pathological processes of vessel formation, such as atherosclerosis, wound healing, rheumatoid arthritis and psoriasis. In a genetic screen for early circulatory system genes in mouse embryonic stem (ES) cells and embryos, we identified the novel zinc finger gene, Vascular endothelial zinc finger 1 (Vezfl). VEZF1 is a 56 KD zinc finger transcription factor that binds in a sequence-specific manner to CT/GC-rich regions in the IL-3 promoter as well as in several promoters from endothelial-specific genes. Its expression during embryogenesis is restricted to vascular endothelial cells and their mesodermal precursors in the yolk sac blood islands. In adults, Vezfl is expressed at reduced levels in the endothelium of the capillaries and mature vessels. It is also expressed in bone marrow megakaryocytes. Vezfl is induced during arterial injury and tumor angiogenesis. In light of its restricted pattern of expression we hypothesize that Vezfl regulates molecular processes during the determination and/or differentiation of the vascular endothelial lineage. In support of our hypothesis, molecular genetic approaches including loss- and gain-of-function mutations of Vezfl in mouse embryos indicate that Vezfl acts in a dosage-dependent manner and is required for the normal proliferation, remodeling, and integrity of the vasculature. To better understand the role of Vezfl during vascular development, we propose to study in detail how Vezfl participates in the molecular pathways that control blood vessel formation. We will identify and characterize regulatory regions within the Vezfl gene that are required and sufficient for endothelial, and megakaryocyte specific expression. We will isolate and characterize proteins that functionally interact with these regulatory regions. Finally, we will identify candidate target genes that are regulated by VEZF1.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Program Officer
Goldman, Stephen
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code
Zou, Zhongmin; Ocaya, Pauline A; Sun, Huiqin et al. (2010) Targeted Vezf1-null mutation impairs vascular structure formation during embryonic stem cell differentiation. Arterioscler Thromb Vasc Biol 30:1378-88
Leong, Hon Sing; Steinmetz, Nicole F; Ablack, Amber et al. (2010) Intravital imaging of embryonic and tumor neovasculature using viral nanoparticles. Nat Protoc 5:1406-17
Brunel, Florence M; Lewis, John D; Destito, Giuseppe et al. (2010) Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting. Nano Lett 10:1093-7
Durrans, Anna; Stuhlmann, Heidi (2010) A role for Egfl7 during endothelial organization in the embryoid body model system. J Angiogenes Res 2:4
Gowher, Humaira; Stuhlmann, Heidi; Felsenfeld, Gary (2008) Vezf1 regulates genomic DNA methylation through its effects on expression of DNA methyltransferase Dnmt3b. Genes Dev 22:2075-84
Zijlstra, Andries; Lewis, John; Degryse, Bernard et al. (2008) The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 13:221-34
Kuhnert, Frank; Stuhlmann, Heidi (2004) Identifying early vascular genes through gene trapping in mouse embryonic stem cells. Curr Top Dev Biol 62:261-81